JAZZ Profile
Jazz Pharmaceuticals plc, headquartered in Dublin, Ireland, operates as a prominent biopharmaceutical company specializing in identifying, developing, and commercializing innovative pharmaceutical products aimed at addressing diverse unmet medical needs across the United States, Europe, and international markets. Established in 2003, Jazz Pharmaceuticals boasts a robust portfolio and pipeline focused on neuroscience, encompassing therapies for sleep disorders and movement disorders, as well as oncology treatments targeting hematologic and solid tumors.
At the forefront of its product offerings are several key marketed treatments. Xyrem, an oral solution, stands out as a pivotal therapy for managing cataplexy and excessive daytime sleepiness in narcolepsy patients aged seven and older. Sunosi, another significant product, addresses excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea. Jazz Pharmaceuticals also markets Erwinaze for acute lymphoblastic leukemia, Defitelio for hepatic veno-occlusive disease, Vyxeos liposome for therapy-related acute myeloid leukemia, and Zepzelca for metastatic small cell lung cancer.
In addition to its marketed products, Jazz Pharmaceuticals continues to advance its pipeline with promising candidates. Xywav, an oxybate product candidate, targets excessive daytime sleepiness and cataplexy linked to narcolepsy and idiopathic hypersomnia. The company is also developing JZP-324, a low sodium oxybate formulation, and JZP385, a T-type calcium channel modulator, offering potential advancements in treating essential tremor. Furthermore, Jazz Pharmaceuticals is focused on JZP458, a recombinant Erwinia asparaginase, which plays a crucial role in multi-agent chemotherapeutic regimens for pediatric and adult patients.
With a commitment to innovation and therapeutic excellence, Jazz Pharmaceuticals maintains strategic licensing and collaboration agreements with industry leaders such as ImmunoGen, Inc., Codiak BioSciences, Inc., Pfenex, Inc., XL-protein GmbH, and Redx Pharma plc. These partnerships underscore the company's dedication to expanding treatment options and advancing patient care across its specialized therapeutic areas.
|
